Shuting Xia

5.6k total citations · 5 hit papers
58 papers, 3.8k citations indexed

About

Shuting Xia is a scholar working on Molecular Biology, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Shuting Xia has authored 58 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 15 papers in Surgery and 11 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Shuting Xia's work include Lipoproteins and Cardiovascular Health (10 papers), Lipid metabolism and disorders (8 papers) and Cancer, Lipids, and Metabolism (6 papers). Shuting Xia is often cited by papers focused on Lipoproteins and Cardiovascular Health (10 papers), Lipid metabolism and disorders (8 papers) and Cancer, Lipids, and Metabolism (6 papers). Shuting Xia collaborates with scholars based in United States, China and Canada. Shuting Xia's co-authors include Sotirios Tsimikas, Joseph L. Witztum, Nicholas J. Viney, Richard S. Geary, Kathie M. Bishop, Ewa Karwatowska‐Prokopczuk, Erik S.G. Stroes, Steven G. Hughes, Eugene Schneider and Louis O’Dea and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Communications.

In The Last Decade

Shuting Xia

49 papers receiving 3.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study

2016 736 citations Richard S. Finkel, Claudia A. Chiriboga et al. The Lancet profile →
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

2020 641 citations Sotirios Tsimikas, Ewa Karwatowska‐Prokopczuk et al. profile →
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

2016 544 citations Nicholas J. Viney, Julian C. van Capelleveen et al. The Lancet profile →
Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol

2022 123 citations Calvin Yeang, Ewa Karwatowska‐Prokopczuk et al. Journal of the American College of Cardiology profile →
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome

2024 112 citations Ewa Karwatowska‐Prokopczuk, Thomas A Prohaska et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shuting Xia United States	25	1.8k	1.5k	929	891	651	58	3.8k
Masaki Ieda Japan	34	2.2k 1.2×	4.1k 2.8×	2.1k 2.2×	312 0.4×	85 0.1×	264	6.6k
Carmen Pérez-Terzic United States	37	1.3k 0.7×	3.7k 2.5×	980 1.1×	504 0.6×	54 0.1×	76	5.5k
M. A. Pericak‐Vance United States	24	853 0.5×	2.7k 1.8×	227 0.2×	1.3k 1.4×	199 0.3×	57	7.1k
Timothy J. Nelson United States	33	1.2k 0.7×	3.2k 2.1×	617 0.7×	384 0.4×	51 0.1×	99	4.6k
Sergio Li Calzi United States	29	640 0.3×	1.5k 1.0×	144 0.2×	212 0.2×	680 1.0×	59	2.9k
Ute I. Scholl Germany	29	1.4k 0.7×	2.0k 1.3×	525 0.6×	88 0.1×	1.6k 2.5×	55	4.1k
Michael P. Murphy United States	24	848 0.5×	1.3k 0.9×	244 0.3×	689 0.8×	95 0.1×	72	3.6k
Catherine Léon France	37	390 0.2×	987 0.7×	1.2k 1.3×	310 0.3×	216 0.3×	77	4.1k
Vardiella Meiner Israel	31	1.1k 0.6×	1.1k 0.8×	243 0.3×	111 0.1×	276 0.4×	128	3.2k
Anne Pizard France	25	312 0.2×	1.2k 0.8×	975 1.0×	334 0.4×	254 0.4×	39	2.3k

Countries citing papers authored by Shuting Xia

Since Specialization

Citations

This map shows the geographic impact of Shuting Xia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shuting Xia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shuting Xia more than expected).

Fields of papers citing papers by Shuting Xia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shuting Xia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shuting Xia. The network helps show where Shuting Xia may publish in the future.

Co-authorship network of co-authors of Shuting Xia

This figure shows the co-authorship network connecting the top 25 collaborators of Shuting Xia. A scholar is included among the top collaborators of Shuting Xia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shuting Xia. Shuting Xia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Yiqing, et al.. (2025). The first-trimester triglyceride glucose-body mass index is a valuable predictor for adverse pregnancy outcomes. BMC Pregnancy and Childbirth. 25(1). 142–142. 1 indexed citations

Yang, Yang, Yimin Cai, Yanmin Li, et al.. (2025). Genetic architecture of bone marrow fat fraction implies its involvement in osteoporosis risk. Nature Communications. 16(1). 7490–7490.

Li, Shengkai, Shuting Xia, Lulu Hu, et al.. (2025). Emergence of carbapenem-resistant XDR Salmonella enterica in paediatric patients in South China: A genomic perspective study. International Journal of Antimicrobial Agents. 66(5). 107589–107589.

Su, Chang‐Yuan, Hemian Yi, Hao‐Fei Ni, et al.. (2025). Two-dimensional lead-free double perovskite ferroelastics with dynamic thermochromism. Chemical Science. 16(48). 23385–23393.

Zhang, Zhengwei, et al.. (2025). Cross-scale synergistic optimization for irrigation allocation and fertilizer management under uncertainty. Agricultural Water Management. 317. 109672–109672.

Xia, Shuting, et al.. (2025). Unlocking the healthy human microbiome: Redefining core microbial signatures. Acta Pharmaceutica Sinica B. 15(2). 1189–1192. 2 indexed citations

Baker, Brenda F., Shuting Xia, Jeffery A. Engelhardt, et al.. (2024). Safety and Tolerability of GalNAc ₃ -Conjugated Antisense Drugs Compared to the Same-Sequence 2′- O -Methoxyethyl-Modified Antisense Drugs: Results from an Integrated Assessment of Phase 1 Clinical Trial Data. Nucleic Acid Therapeutics. 34(1). 18–25. 4 indexed citations

Prohaska, Thomas A, Veronica J. Alexander, Ewa Karwatowska‐Prokopczuk, et al.. (2023). APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia. Journal of clinical lipidology. 17(3). 406–411. 36 indexed citations

Li, Zao, et al.. (2023). Research on the Spatial Sequence of Building Facades in Huizhou Regional Traditional Villages. Buildings. 13(1). 174–174. 18 indexed citations

10.

Baker, Brenda F., Shuting Xia, T. Jesse Kwoh, et al.. (2022). Integrated Assessment of Phase 2 Data on GalNAc ₃ -Conjugated 2′- O -Methoxyethyl-Modified Antisense Oligonucleotides. Nucleic Acid Therapeutics. 33(1). 72–80. 11 indexed citations

11.

Yeang, Calvin, Ewa Karwatowska‐Prokopczuk, Fei Su, et al.. (2022). Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology. 79(11). 1035–1046. 123 indexed citations breakdown →

12.

Zhou, Zikai, Guiqin He, Xin Lv, et al.. (2021). NGPF2 triggers synaptic scaling up through ALK-LIMK-cofilin-mediated mechanisms. Cell Reports. 36(7). 109515–109515. 7 indexed citations

13.

Xia, Shuting, et al.. (2021). Improvements in the Tolerability Profile of 2′- O -Methoxyethyl Chimeric Antisense Oligonucleotides in Parallel with Advances in Design, Screening, and Other Methods. Nucleic Acid Therapeutics. 31(6). 417–426. 8 indexed citations

14.

Zhang, Zi Chao, An Liu, Shuting Xia, et al.. (2021). PQBP1 promotes translational elongation and regulates hippocampal mGluR-LTD by suppressing eEF2 phosphorylation. Molecular Cell. 81(7). 1425–1438.e10. 23 indexed citations

15.

Curtis, Brian R., Lijiang Shen, Eugene Schneider, et al.. (2020). Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia. Nucleic Acid Therapeutics. 30(2). 94–103. 26 indexed citations

16.

Gong, Siyi, et al.. (2020). Light therapy: a new option for neurodegenerative diseases. Chinese Medical Journal. 134(6). 634–645. 18 indexed citations

17.

Alexander, Veronica J., Shuting Xia, Eunju Hurh, et al.. (2019). N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. European Heart Journal. 40(33). 2785–2796. 183 indexed citations

18.

Finkel, Richard S., Claudia A. Chiriboga, Jiri Vajsar, et al.. (2016). Interim Results of a Phase 2 Clinical Study of Nusinersen (ISIS-SMNRx) in Patients with Infantile-Onset Spinal Muscular Atrophy (P5.004). Neurology. 86(16_supplement). 5 indexed citations

19.

Viney, Nicholas J., Julian C. van Capelleveen, Richard S. Geary, et al.. (2016). Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. The Lancet. 388(10057). 2239–2253. 544 indexed citations breakdown →

20.

Gao, Yuzhen, et al.. (2005). Genetic Characteristics of Three New Y-STRs: DYS631, DYS634 and DYS635 in a Chinese Population. Journal of Forensic Sciences. 50(6). JFS2005204–2. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact